Turning Point Therapeutics, Inc.
COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDS
Last updated:
Abstract:
The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.
Status:
Application
Type:
Utility
Filling date:
25 Nov 2020
Issue date:
22 Jul 2021